OncoSil Medical Limited (ASX:OSL)

Market Cap	13.60M -40.8%
Revenue (ttm)	1.54M -1.9%
Net Income	-15.10M
EPS	-1.38
Shares Out	18.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	307,005
Average Volume	58,076
Open	0.7400
Previous Close	0.7100
Day's Range	0.7000 - 0.7400
52-Week Range	0.6900 - 2.8000
Beta	1.23
RSI	32.12
Earnings Date	Feb 27, 2026

About OncoSil Medical

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OSL

Financial Performance

In fiscal year 2025, OncoSil Medical's revenue was 1.54 million, a decrease of -1.92% compared to the previous year's 1.57 million. Losses were -15.10 million, 26.7% more than in 2024.